Indication
Hepcludex is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult and paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease.
Loading your page…
Hepatitis D, Chronic
Marketing Authorisation Holder: Gilead Sciences Ireland UC
EMA Authorisation: 31/07/2020
INN: bulevirtide
AI Drug & Interaction Analysis
Free account required
Ask Osler about Hepcludex: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.